"Glucosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D005960
|
| MeSH Number(s) |
D09.408.348
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucosides".
Below are MeSH descriptors whose meaning is more specific than "Glucosides".
This graph shows the total number of publications written about "Glucosides" by people in this website by year, and whether "Glucosides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 1 | 4 |
| 2021 | 3 | 3 | 6 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucosides" by people in Profiles.
-
Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice? Cardiovasc Drugs Ther. 2024 Aug; 38(4):769-770.
-
The national financial burden of guideline directed medical therapy for heart failure patients from 2013 to 2021. Curr Probl Cardiol. 2024 Aug; 49(8):102684.
-
Dapagliflozin for Atrial Fibrillation. Cardiovasc Drugs Ther. 2024 Feb; 38(1):1-3.
-
Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2025 Feb; 39(1):43-61.
-
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
-
Development of a novel UPLC-MS/MS method for the simultaneously quantification of polydatin and resveratrol in plasma: Application to a pharmacokinetic study in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Nov 15; 1185:123000.
-
An in vivo and in vitro model on the protective effect of corilagin on doxorubicin-induced cardiotoxicity via regulation of apoptosis and PI3-K/AKT signaling pathways. J Biochem Mol Toxicol. 2021 Dec; 35(12):e22926.
-
Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2022 10; 36(5):829-840.
-
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. Diabetes Obes Metab. 2021 06; 23(6):1426-1430.
-
Early eGFR decline after SGLT2i initiation: knowns and unknowns. Kidney Int. 2021 03; 99(3):548-550.